Tango Therapeutics, Inc. (TNGX)
NASDAQ: TNGX · Real-Time Price · USD
1.460
-0.010 (-0.68%)
Apr 24, 2025, 4:00 PM EDT - Market closed
Company Description
Tango Therapeutics, Inc., a precision oncology company, focuses on the discovery and development of drugs in defined patient populations with unmet medical need.
The company develops methylthioadenosine -cooperative protein arginine methyltransferase 5 (PRMT5) inhibitors, including TNG462, which is in Phase 1/2 clinical trial for treating pancreatic and lung cancer; and TNG456, a brain-penetrant PRMT5 inhibitor for the treatment of glioblastoma.
It is developing TNG260, a co-repressor of repressor element-1 silencing transcription inhibitor to reverse the immune evasion effect of serine-threonine kinase 11 loss-of-function mutations for treating lung cancer.
The company was founded in 2017 and is headquartered in Boston, Massachusetts.
Tango Therapeutics, Inc.
| Country | United States |
| Founded | 2014 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 155 |
| CEO | Barbara Weber |
Contact Details
Address: 201 Brookline Avenue, Suite 901 Boston, Massachusetts 02215 United States | |
| Phone | 857 320 4900 |
| Website | tangotx.com |
Stock Details
| Ticker Symbol | TNGX |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001819133 |
| CUSIP Number | 87583X109 |
| ISIN Number | US87583X1090 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Barbara L. Weber M.D. | President, Chief Executive Officer and Director |
| Dr. Adam S. Crystal M.D., Ph.D. | President of Research and Development |
| Dr. Alan Ashworth FRS, Ph.D. | Founder and Member of Scientific Advisory Board |
| Dr. William G. Kaelin Jr., M.D. | Founder and Member of Scientific Advisory Board |
| Dr. Antoni Ribas M.D., Ph.D. | Founder and Member of Scientific Advisory Board |
| Timothy Redfern | Chief Financial Officer |
| Dr. Michael Palmieri Ph.D. | Head of Technical Operations |
| Jannik N. Andersen Ph.D. | Chief Scientific Officer |
| Elizabeth Pingpank Hickin | Vice President of IR and Corporate Communications |
| Douglas J. Barry Esq., J.D. | Chief Legal Officer, Chief Compliance Officer and Corporate Secretary |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 24, 2025 | DEFR14A | Filing |
| Apr 22, 2025 | ARS | Filing |
| Apr 22, 2025 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 21, 2025 | DEF 14A | Other definitive proxy statements |
| Apr 11, 2025 | PRE 14A | Other preliminary proxy statements |
| Feb 27, 2025 | S-8 | Securities to be offered to employees in employee benefit plans |
| Feb 27, 2025 | 10-K | Annual Report |
| Feb 27, 2025 | 8-K | Current Report |
| Feb 14, 2025 | SCHEDULE 13G/A | Filing |
| Jan 13, 2025 | 8-K | Current Report |